Avacta Reports Positive Phase 1a Results for AVA6000 in Salivary Gland Cancer

The latest update is out from Avacta Group plc ( (GB:AVCT) ).

Avacta Therapeutics has announced promising results from the Phase 1a trial of AVA6000, a peptide drug conjugate designed to treat salivary gland cancer (SGC) among other solid tumors. The trial demonstrated clinically significant tumor shrinkage in half of the patients treated, with a 90% disease control rate. AVA6000 was found to be well-tolerated with reduced hematologic and cardiac toxicities compared to conventional doxorubicin. Based on these results, Avacta has initiated Phase 1b expansion cohorts to further explore the drug’s potential in treating triple negative breast cancer, soft tissue sarcoma, and SGC.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company that focuses on developing next-generation peptide drug conjugates (PDCs) using its proprietary pre|CISION® platform. This platform targets cancer treatment by delivering highly potent anti-tumor payloads directly to the tumor microenvironment, minimizing exposure to healthy tissues. Avacta’s pipeline includes innovative PDCs and Affimer® drug conjugates, which leverage tumor-specific release mechanisms, offering advantages over traditional antibody drug conjugates.

YTD Price Performance: 1.00%

Average Trading Volume: 1,615,223

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £184.8M

For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.